158 related articles for article (PubMed ID: 8753686)
1. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.
Rösch F; Herzog H; Plag C; Neumaier B; Braun U; Müller-Gärtner HW; Stöcklin G
Eur J Nucl Med; 1996 Aug; 23(8):958-66. PubMed ID: 8753686
[TBL] [Abstract][Full Text] [Related]
2. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.
Herzog H; Rösch F; Stöcklin G; Lueders C; Qaim SM; Feinendegen LE
J Nucl Med; 1993 Dec; 34(12):2222-6. PubMed ID: 8254415
[TBL] [Abstract][Full Text] [Related]
3. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.
Rösch F; Herzog H; Stolz B; Brockmann J; Köhle M; Mühlensiepen H; Marbach P; Müller-Gärtner HW
Eur J Nucl Med; 1999 Apr; 26(4):358-66. PubMed ID: 10199941
[TBL] [Abstract][Full Text] [Related]
4. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
5. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
6. Internal dosimetry studies of
Shirmardi SP; Saniei E; Das T; Noorvand M; Erfani M; Bagheri R
Appl Radiat Isot; 2020 Dec; 166():109396. PubMed ID: 32889376
[TBL] [Abstract][Full Text] [Related]
7. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
8. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
Keeling AA; Vaughan AT; Beaney RP
Br J Cancer; 1989 Jul; 60(1):74-8. PubMed ID: 2803919
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
11. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
12. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of pains from bone metastases with 90Y (author's transl)].
Kutzner J; Dähnert W; Schreyer T; Grimm W; Brod KH; Becker M
Nuklearmedizin; 1981 Oct; 20(5):229-35. PubMed ID: 6171780
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma detection and systemic therapy with tumour-affine gallium-67 and with yttrium-90 citrate solutions.
Shukla SK; Limouris GS; Cusumano R; Acconcia A; Cipriani C; Argiro G; Atzei G; Boemi S
Anticancer Res; 1997; 17(3B):1713-8. PubMed ID: 9179224
[TBL] [Abstract][Full Text] [Related]
15. 153Sm-EDTMP for bone pain palliation in skeletal metastases.
Maini CL; Bergomi S; Romano L; Sciuto R
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous study of the biodistribution of radio-yttrium complexed with EDTMP and citrate ligands in tumour-bearing rats.
Beyer GJ; Bergmann R; Kampf G; Mäding P; Rösch F
Int J Rad Appl Instrum B; 1992 Feb; 19(2):201-3. PubMed ID: 1601673
[TBL] [Abstract][Full Text] [Related]
18. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
19. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
20. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
